2025 Press Releases 2025 2024 2023 2022 2021 Portfolio Companies New Leaf Portfolio Companies CuraSen Therapeutics Doses First Patient with CuraAX (CST-3056) in Phase 2a Neurogenic Orthostatic Hypotension (nOH) StudyOctober 23, 2025 Electra Therapeutics Announces $183 Million Series C Financing to Advance First-in-Class SIRP-Targeted Therapies for Immune Disorders and CancerOctober 22, 2025 TigerConnect Secures FDA 510(K) Clearance For Industry’s First Cloud-Native Alarm Management Solution October 7, 2025 Kyruus Health and Healthgrades Partner to Improve Patient Access and Digital Presence for Healthcare ProvidersOctober 1, 2025 RevSpring to Acquire Kyruus Health, Creating a Connected Care Journey from Search to Final PaymentSeptember 23, 2025 STAR THERAPEUTICS ANNOUNCES OVERSUBSCRIBED $125 MILLION SERIES D FINANCINGSeptember 30, 2025 TigerConnect Launches Patient Coordination Product To Streamline Interfacility TransferSeptember 4, 2025 TigerConnect Acquires EVideon To Power The Next-Generation Of Smart Room SolutionsAugust 26, 2025 Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular DystrophiesJune 26, 2025 Arvinas and Pfizer’s Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast CancerMay 31, 2025 Kalderos Names Healthcare Industry Veteran Daryl Todd as Chief Strategy OfficerMay 14, 2025 TigerConnect Strengthens Global Presence with New Mexico City OfficeMay 13, 2025 TigerConnect Appoints Sean O’Neal as CEO, Marking a Bold New Chapter of Innovation and GrowthMay 1, 2025 Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common StockApril 2, 2025 Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM)April 2, 2025 Cleerly Unveils Groundbreaking Late-Breaking Clinical Trial Results Demonstrating AI-QCT’s Predictive Power for Women’s Cardiovascular Risk at ACC.25March 31, 2025 Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical TrialMarch 11, 2025 TigerConnect to Launch Pre-Hospital and Transfer Solutions to Streamline Emergency Care Coordination and Improve Patient Throughput at HIMSS 25February 27, 2025 CuraSen Therapeutics Announces First Subject Treated with CuraAX (CST-3056) in a Phase 1 Clinical TrialFebruary 20, 2025 Kyruus Health and aha! Announce Partnership to Enhance Patient Access and EngagementFebruary 13, 2025 Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical TrialFebruary 11, 2025 Kyruus Health Achieves Record Growth as Searches for Care Surpass 1 BillionFebruary 5, 2025 Qlaris Bio Announces Positive Topline Data From Two Phase II Trials Of QLS-111 In Patients With Primary Open Angle Glaucoma And Ocular HypertensionFebruary 5, 2025 Bluesight Expands Compliance Capabilities and Strengthens Platform through Acquisition of ProtenusJanuary 9, 2025 Star Therapeutics Receives FDA Fast Track Designation for VGA039 in Von Willebrand Disease (VWD)January 6, 2025
